Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

158.75
Net Asset Value
+0.31%
1 Day
+2.53%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.65%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month+5.80% 3 years-2.59%
3 months-3.18% 5 years+13.26%
1 year+12.47% Since inception+13.31%
Data through --

Peer Comparisonvs. Health

 FRBRXCategory
Performance 5-yr return+13.26%+14.29%
Expense ratio0.65%1.29%
Risk 5 year sharpe ratio0.600.89
Net assets$1.3B$2.9B
Average market cap$7.6B$9.8B
Average P/E--22.0
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--

Holdings

U.S. stock91.87%
International stock4.59%
Cash3.54%
Fixed income0.01%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
ALXN Alexion Pharmaceuticals Inc7.69%
CELG Celgene6.86%
VRTX Vertex Pharmaceuticals Inc4.96%
BIIB Biogen4.87%
ILMN Illumina Inc4.07%
REGN Regeneron Pharmaceuticals3.52%
GILD Gilead Sciences3.39%
AMGN Amgen3.33%
HRTX Heron Therapeutics Inc3.30%
BMRN Biomarin Pharmaceutical Inc2.85%